Articolul precedent |
Articolul urmator |
440 0 |
SM ISO690:2012 TOMACINSCHII, Victor, ROBU, Maria, MUSTEAŢĂ, Vasile, MOCANU, Irina, SPORÎȘ, Natalia , SPORÎȘ, Natalia. Secondary acute promielocytic leukemia developed after treatment of non-hodgkin's lymphoma, case study and review of literature. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 270. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | |||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | |||||
|
|||||
Pag. 270-270 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Background. Acute promyelocytic leukemia (APL) is an acute myeloid leukemia (AML) that accounts approximately 10-15% of AML cases. APL usually appears as an de novo finding. The occurrence of secondary APL(sAPL) after chemotherapy(PChT) is rare, and the development of sAPL after an NHL is casuistic. Objective of the study. Description of a case of sAPL after NHL therapy. Material and Methods. The morphological blocks of lymph node biopsy, CBC and bone marrow aspiration (bma) were investigated. Results. Male B, 34 years old, hospitalized in a critical condition in the hematological center with Diffuse large B cell lymphoma, stage IV B, X (Ann-Arbor). With the purpose of induction, PChT cures were performed: R-CHOP, R-CHOEP, CVP, obtaining partial remission. 25 months after the onset of NHL, the patient experienced: anemia, thrombocytopenia, leukocytosis associated with peripheral blastosis. For restadialization an bma was performed, which reveals 95% of promyelocytetype blasts. sAPL was confirmed, induction PChT was initiated, still the result proved no efficacy. The death occurred early in induction, which corresponds with literature data. Conclusion. sAPL after NHL therapy are rare nosological entities in clinical practice, which are associated with the negative effect of treatment with anthracyclines or tenoposide derivatives, results in unfavorable prognosis and high mortality. |
|||||
Cuvinte-cheie secondary acute promyelocytic leukemia, non-Hodgkin's lymphoma, leucemie acută promielocitară secundară, limfom non-Hodgkin |
|||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Tomacinschii, V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Robu, M.V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Musteaţă, V.G.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Mocanu, I.</creatorName> <affiliation>IMSP Institutul Oncologic, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Sporîș, N.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Sporîș, N.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='en,ro'>Secondary acute promielocytic leukemia developed after treatment of non-hodgkin's lymphoma, case study and review of literature</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2020</publicationYear> <relatedIdentifier relatedIdentifierType='ISBN' relationType='IsPartOf'></relatedIdentifier> <subjects> <subject>secondary acute promyelocytic leukemia</subject> <subject>non-Hodgkin's lymphoma</subject> <subject>leucemie acută promielocitară secundară</subject> <subject>limfom non-Hodgkin</subject> </subjects> <dates> <date dateType='Issued'>2020</date> </dates> <resourceType resourceTypeGeneral='Text'>Conference Paper</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>Background. Acute promyelocytic leukemia (APL) is an acute myeloid leukemia (AML) that accounts approximately 10-15% of AML cases. APL usually appears as an de novo finding. The occurrence of secondary APL(sAPL) after chemotherapy(PChT) is rare, and the development of sAPL after an NHL is casuistic. Objective of the study. Description of a case of sAPL after NHL therapy. Material and Methods. The morphological blocks of lymph node biopsy, CBC and bone marrow aspiration (bma) were investigated. Results. Male B, 34 years old, hospitalized in a critical condition in the hematological center with Diffuse large B cell lymphoma, stage IV B, X (Ann-Arbor). With the purpose of induction, PChT cures were performed: R-CHOP, R-CHOEP, CVP, obtaining partial remission. 25 months after the onset of NHL, the patient experienced: anemia, thrombocytopenia, leukocytosis associated with peripheral blastosis. For restadialization an bma was performed, which reveals 95% of promyelocytetype blasts. sAPL was confirmed, induction PChT was initiated, still the result proved no efficacy. The death occurred early in induction, which corresponds with literature data. Conclusion. sAPL after NHL therapy are rare nosological entities in clinical practice, which are associated with the negative effect of treatment with anthracyclines or tenoposide derivatives, results in unfavorable prognosis and high mortality.</p></description> <description xml:lang='ro' descriptionType='Abstract'><p>Introducere. Leucemia acută promielocitară (LAP) e o leucemie acută mieloidă (LAM) ce însumează aproximativ 10-15% din cazurile de LAM. LAP, de obicei, survine de novo. Apariția LAP secundare (LAPs) după tratamentul chimioterapic (PChT) are loc rar, iar dezvoltarea LAPs după un LNH este cazuistic. Scopul lucrării. Descrierea unui caz de LAPs secundar unui LNH. Material și Metode. Au fost investigate blocurile morfologice ale biopsiei ganglionului limfatic, hemograma și aspiratul medular (a.m.). Rezultate. Bărbat B, 34 ani a fost spitalizat în stare foarte gravă în cadrul centrului hematologic cu diagnosticul de LNH difuz cu celula mare B, stadiu IV B,X (Ann-Arbor). Cu scop de inducere au fost efectuate cure de PChT de tip: R-CHOP, R-CHOEP, CVP cu obținerea remisiunii parțiale. La 25 de luni după debutul LNH, pacientul subit dezvoltă: anemie, trombocitopenie, leucocitoză asociată cu blastoză periferică. Pentru restadializare se efectuează a.m., care relevă 95% de blaști de tip promielocite. S-a confirmat LAPs, s-a inițiat PChT de inducere, fără eficacitate. Decesul a survenit, precoce, în inducere, ceea ce corespunde cu datele literaturii. Concluzii. LAP secundare LNH sunt entități nozologice rarisime în practica clinică, ce pot fi asociate efectului negativ al tratamentului cu antracicline sau derivați de tenoposid cu un prognostic nefavorabil și o mortalitate înaltă.</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>